Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotigotine transdermal - UCB

Drug Profile

Rotigotine transdermal - UCB

Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962

Latest Information Update: 06 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aderis Pharmaceuticals
  • Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 20 Jun 2019 UCB Pharma plans a phase III trial for Restless Legs Syndrome (In adolescents) in November 2018 (Transdermal) (NCT03992196)
  • 20 Dec 2018 Phase-III clinical trials in Restless legs syndrome (In adolescents) in USA (Transdermal) (NCT03728933)
  • 02 Nov 2018 UCB Pharma plans a phase III trial for Restless Legs Syndrome (In adolescents) in November 2018 (Transdermal) (NCT03728933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top